Soleno Therapeutics (SLNO) announced that the U.S. Food and Drug Administration, FDA, has extended the review period for the New Drug Application, NDA, for DCCR extended-release tablets for the treatment of Prader-Willi syndrome, PWS, in individuals four years and older who have hyperphagia. The new Prescription Drug User Fee Act, PDUFA, target action date is March 27, 2025.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO: